OGN

Organon (OGN)

Organon and Co

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NYSE:OGN

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/18	05:15	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:OGN	Organon and Co
2024/05/08	09:20	Business Wire	Organon Announces Pricing of $1.0 Billion Senior Notes Offering	NYSE:OGN	Organon and Co
2024/05/08	05:07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
2024/05/08	05:07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
2024/05/08	05:06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
2024/05/08	05:06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
2024/05/08	05:06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
2024/05/08	05:05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
2024/05/08	05:05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
2024/05/07	20:58	Business Wire	Organon Announces Proposed $1.0 Billion Senior Notes Offering	NYSE:OGN	Organon and Co
2024/05/02	20:30	Business Wire	Organon Reports Results for the First Quarter Ended March 31, 2024	NYSE:OGN	Organon and Co
2024/04/09	21:13	Business Wire	Prolia ® とXgeva ® （デノスマブ）との第3相比較臨床試験でバイオシミラー候補HLX14が主要評価項目を達成	NYSE:OGN	Organon and Co
2024/04/09	03:31	Business Wire	Klinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre Endpunkte	NYSE:OGN	Organon and Co
2024/04/09	03:31	Business Wire	L'essai clinique comparatif de phase 3 du candidat biosimilaire de Prolia ® et de Xgeva ® (denosumab) HLX14 remplit les critères d'évaluation primaires	NYSE:OGN	Organon and Co
2024/04/08	19:15	Business Wire	Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024	NYSE:OGN	Organon and Co
2024/04/08	19:00	Business Wire	Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints	NYSE:OGN	Organon and Co
2024/03/08	23:01	PR Newswire (Canada)	À l'occasion de la Journée internationale des femmes, Organon Canada encourage les entreprises à Investir en elle et à lutter contre les inégalités entre les genres par la santé des femmes	NYSE:OGN	Organon and Co
2024/03/08	23:01	PR Newswire (Canada)	On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health	NYSE:OGN	Organon and Co
2024/03/02	06:24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
2024/03/02	06:24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
2024/03/02	06:22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
2024/03/02	06:22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
2024/02/26	22:10	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NYSE:OGN	Organon and Co
2024/02/24	01:46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
2024/02/20	22:00	Business Wire	Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary	NYSE:OGN	Organon and Co
2024/02/15	21:48	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:OGN	Organon and Co
2024/02/15	21:30	Business Wire	Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023	NYSE:OGN	Organon and Co
2024/02/14	06:16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:OGN	Organon and Co
2024/02/01	21:30	Business Wire	Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024	NYSE:OGN	Organon and Co
2024/01/10	21:33	Business Wire	Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older	NYSE:OGN	Organon and Co